541 reports of this reaction
2.4% of all RIFAMPIN reports
#7 most reported adverse reaction
PYREXIA is the #7 most commonly reported adverse reaction for RIFAMPIN, manufactured by Sanofi-Aventis U.S. LLC. There are 541 FDA adverse event reports linking RIFAMPIN to PYREXIA. This represents approximately 2.4% of all 22,393 adverse event reports for this drug.
Patients taking RIFAMPIN who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is a less commonly reported adverse event for RIFAMPIN, but still significant enough to appear in the safety profile.
In addition to pyrexia, the following adverse reactions have been reported for RIFAMPIN:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 541 FDA reports for RIFAMPIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 2.4% of all adverse event reports for RIFAMPIN, making it a notable side effect.
If you experience pyrexia while taking RIFAMPIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.